Bluprynt | $4,250,000 | (Feb 27, 2026)
UpGuard | $75,000,000 | (Feb 27, 2026)
Revel(US) | $150,000,000 | (Feb 27, 2026)
Certified by Founder
Lodge
MBrace Therapeutics
start up
United States
- San Diego, California
- 15/11/2023
- Series B
- $85,000,000
MBrace Therapeutics is a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. MBrace is supported by a world-class investor syndicate, including TPG, Avidity Partners, Cowen Healthcare Investments, Venrock and Alta Partners.
- Industry Biotechnology Research
- Website https://mbracetrx.com/
- LinkedIn https://www.linkedin.com/company/mbrace-therapeutics/about/
Alpa | $3,500,000 | (Feb 27, 2026)
ElastixAI | $18,000,000 | (Feb 27, 2026)
Callosum | $10,250,000 | (Feb 27, 2026)
JetScale AI | $5,400,000 | (Feb 27, 2026)
Dots | $8,900,000 | (Feb 27, 2026)
VITURE | $100,000,000 | (Feb 27, 2026)
Ark Climate | $2,478,315 | (Feb 27, 2026)
Jest | $7,000,000 | (Feb 27, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)